Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Osteoporosis 2With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1Uterine Cervical Dysplasia 1Precancerous Conditions 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Hereditary Breast and Ovarian Cancer Syndrome 1

Interventions

Psychiatric Rehabilitation 4Flow Cytometry 3Early Intervention, Educational 3Surveys and Questionnaires 2Methylprednisolone 2Methods 2Melphalan 2Immunologic Techniques 2Gene Expression Profiling 2Cyclophosphamide 2Counseling 2Bupropion 2Blood Specimen Collection 2Azacitidine 2Alemtuzumab 2tanespimycin 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1ixabepilone 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1aldesleukin 1abiraterone 1Zoledronic Acid 1Zinc Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Zoledronic Acid × Gynecologic × Clear all
NCT00321932 2017-03-09

Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

University of Minnesota

Phase 2 Completed
61 enrolled 16 charts
GynecologicLymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡